CytoSorbents Engages in Insightful Virtual Talk
CytoSorbents Corporation (NASDAQ: CTSO), renowned for its pioneering blood purification solutions, is excited to announce an upcoming virtual fireside chat. This event will feature Dr. Phillip Chan, CEO, and CFO Peter J. Mariani engaging with Jason Kolbert from D. Boral Capital. It will provide a platform for discussing the company's recent achievements and strategic advancements.
Significant Growth and Developments
The virtual chat follows the company's impressive third-quarter earnings report, showcasing $37 million in high-margin sales over the trailing twelve months. Additionally, CytoSorbents has bolstered its balance sheet, fueling optimism for its ongoing regulatory processes with the U.S. Food and Drug Administration (FDA) concerning DrugSorb™-ATR. A decision is anticipated in mid-2026, further underscoring the company’s momentum within the industry.
Participation Details for the Virtual Fireside Chat
Event Title: Transforming Critical Care: CytoSorbents' Blood-Purification Programs Deliver Growing Revenues as DrugSorb-ATR Moves Toward a Mid-2026 FDA Review
Date: Monday, December 15, 2025
Time: 11:00 AM – 12:00 PM EST
Registration: Attendees can sign up through the relevant platform to secure a spot for this enlightening session.
About CytoSorbents Corporation
Located in Princeton, New Jersey, CytoSorbents is at the forefront of treating life-threatening conditions prevalent in intensive care units and during cardiac surgeries through revolutionary blood purification technologies. Their innovative solutions utilize biocompatible, highly porous polymer beads that effectively eliminate harmful substances from blood. This technology is accessible through standard hospital blood pumps, ensuring toxicity is efficiently reduced while enhancing patient care.
Applications and Impact of CytoSorbents' Technologies
The technologies offered by CytoSorbents cover a spectrum of medical applications. Key among these is the treatment during and after cardiothoracic surgical procedures, where the removal of blood thinners is crucial to mitigate severe bleeding risks. Furthermore, their solutions are employed to detoxify blood during critical illnesses, including sepsis, trauma, and severe organ dysfunction.
The Success of CytoSorb
CytoSorb, the company’s flagship product, has seen an impressive uptake, with over 300,000 devices utilized across more than 70 countries. Approved in the European Union, it initially received CE mark recognition as a cytokine adsorber, and has since expanded its applications to include the removal of bilirubin, myoglobin, and even toxic metabolites in liver conditions. The company aims to obtain FDA approval for using CytoSorb in critically ill COVID-19 patients, showcasing its commitment to addressing urgent healthcare needs.
Future Directions for DrugSorb™-ATR
In addition to CytoSorb, CytoSorbents is spearheading the development of DrugSorb™-ATR, which focuses on removing antithrombotic agents to minimize the risk of bleeding during high-risk surgeries. This investigational device is crucial for treating patients on blood-thinning medications who face surgeries. Currently seeking approval from both the FDA and Health Canada, DrugSorb-ATR aims to bring revolutionary capability to surgical practices.
Investing in Innovation
CytoSorbents remains committed to scientific progress, with a robust pipeline of products underscored by strong intellectual property protections. Their technologies not only address critical areas in medicine but also underscore the importance of innovation in improving patient outcomes. With numerous products under development and a proactive approach to regulatory approvals, the company is poised for significant advancement in the healthcare field.
Frequently Asked Questions
What is the purpose of the upcoming virtual fireside chat?
The chat aims to provide insights on CytoSorbents' recent performance and future ambitions, particularly focusing on regulatory progress.
How has CytoSorbents performed in the past year?
The company reported $37 million in high-margin sales, indicating strong financial performance amid ongoing product development.
What key products does CytoSorbents offer?
CytoSorbents offers products such as CytoSorb and is developing DrugSorb™-ATR to target bleeding management during surgeries.
What are the implications of the FDA decision due in mid-2026?
This decision is critical as it may lead to expanded use of DrugSorb-ATR and enhance the company's market position significantly.
How can potential investors monitor company updates?
Investors are encouraged to follow CytoSorbents on their various social media channels and their official website for the latest news and developments.
